Latest Intelligence on Therapy Area in South and Central America

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Osteoarthritis: safety concerns over COX-2s will limit uptake

Published By Datamonitor
11 Dec 2006
ResearchWire
ResearchWire

Obesity: lack of reimbursement limits market potential

Published By Datamonitor
09 Feb 2007
CommentWire
CommentWire

Noven: Mesafem emerges as potential alternative to HRT

Recently announced results suggest that Noven's non-hormonal therapy Mesafem is effective in relieving vasomotor symptoms associated with the menopause. However, Datamonitor believes that Mesafem will have to demonstrate equivalent or superior efficacy to hormonal replacement therapy if it is to overcome the challenges in this underserved market.

Published By Datamonitor
17 Jul 2009
CommentWire
CommentWire

Novavax: competitors may follow lead in regional strategy

US biotech Novavax has initiated a pivotal two-stage study for its H1N1 influenza vaccine in Mexico. Novavax's strategy of pursuing approval for the vaccine in smaller markets before targeting the US represents an alternative and faster route to market. Given the many benefits of this strategy, Datamonitor believes that it may be adopted by other small vaccine companies in the future.

Published By Datamonitor
21 Oct 2009
Expert View
Expert View

Novartis: Debiopharm deal strengthens hepatitis C pipeline

Given the high unmet need for novel hepatitis C viral agents, numerous classes and strategies are being investigated. At present, it is unclear where cyclophilin inhibitors will fit into the treatment paradigm. However, Datamonitor believes that Novartis is most likely to benefit from combining Debio 025 with its investigational interferon therapy.

Published By Datamonitor
11 Feb 2010
Expert View
Expert View

New advertising code of conduct established in Vioxx withdrawal fallout

Recent high-profile drug withdrawals have resulted in a new code of conduct to govern direct-to-consumer advertising. As more and more drugs are likely to come under regulatory and public scrutiny, the pharmaceutical industry will need to employ effective marketing and education strategies to ensure patient and physician confidence is retained and the impact of drug safety scares is minimized.

Published By Datamonitor
09 Mar 2006
ResearchWire
ResearchWire

Neuropathic pain: opportunities await despite generic threat

Published By Datamonitor
29 Sep 2006
ResearchWire
ResearchWire

Neuropathic pain: market set to double over next decade

Published By Datamonitor
31 Oct 2007
CommentWire
CommentWire

Nabi: pharmaceutical giants should cough up for smoking vaccine

Positive interim results, assessing the antibody response and safety of a 400mcg, six-dose immunization schedule of Nabi Biopharmaceuticals' NicVAX, provide a new indication of the vaccine's potential to treat nicotine addiction and prevent smoking relapse. These results make the product a more attractive licensing proposition as Nabi gears up to initiate pivotal Phase III trials.

Published By Datamonitor
25 Jul 2008
CommentWire
CommentWire

Nabi/GlaxoSmithKline: deal reignites confidence in nicotine vaccine approach

In securing GlaxoSmithKline's signature, Nabi Biopharmaceuticals has gained the perfect Big Pharma partner to support its NicVAX program. Although Phase III development remains Nabi's responsibility, it provides a timely boost to the validity of the approach, following the recent set-back experienced by Novartis and Cytos with their own nicotine vaccine, NIC-002.

Published By Datamonitor
17 Nov 2009

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.